Concerns that cangliflozin (Invokana) increases the risk of amputations have been allayed in a large retrospective study of the SGLT2 inhibitor versus other drugs in its class and non-SGLT2 inhibitors. The findings from the OBSERVE-4D study were presented at the ADA 78th Scientific Sessions in Orlando and concurrently published in Diabetes, Obesity and Metabolism. Data ...
Type 2 diabetes
“I am now reassured” – SGLT2 inhibitor off the hook re: amputations
By Mardi Chapman
27 Jun 2018